By Connor Hart
Palantir Technologies raised its full-year outlook after posting higher profit and revenue in the second quarter, driven by continuing demand for its artificial intelligence products. The company, which sells AI software to manage and analyze large amounts of data, now expects revenue of $4.14 billion to $4.15 billion for the year, up from a prior outlook of $3.89 billion and $3.9 billion. Wall Street modeled $3.89 billion. Shares rise 4.3%, to $167.52, in after-hours trading.
Hims & Hers Health posted higher profit and revenue in the second quarter, and the company backed its full-year outlook. In the current quarter, the telehealth-consultation platform forecast revenue of $570 million to $590 million, the midpoint of which was below Wall Street models for $583 million. Shares fall 13%, to $54.88, in postmarket trading.
Vertex Pharmaceuticals said it wouldn't progress a next-generation pain treatment into advanced testing after the drug failed to meet its primary endpoint in a recent Phase 2 study. The disclosure overshadowed higher-than-expected second-quarter earnings. The biotechnology company's stock tumbles 15%, to $402.75, in after-hours trading.
Kyndryl delivered a sharply higher profit in the recent quarter as companies continued spending on the company's information-technology infrastructure services. Revenue, though, was roughly flat at $3.74 billion and came in below Wall Street's $3.8 billion estimate. Shares fall 14%, to $31.65, in postmarket trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 04, 2025 19:50 ET (23:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。